Fusion Antibodies PLC
LSE:FAB

Watchlist Manager
Fusion Antibodies PLC Logo
Fusion Antibodies PLC
LSE:FAB
Watchlist
Price: 6.1 GBX -0.81% Market Closed
Market Cap: 6.9m GBX

Net Margin
Fusion Antibodies PLC

-90.3%
Current
-98%
Average
0.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-90.3%
=
Net Income
-1.6m
/
Revenue
1.8m

Net Margin Across Competitors

Fusion Antibodies PLC
Glance View

Market Cap
6.9m GBX
Industry
Life Sciences Tools & Services

Fusion Antibodies Plc engages in the provision of antibody engineering services for all stages of therapeutic and diagnostic antibody development. The company is headquartered in Belfast, Northern Ireland and currently employs 54 full-time employees. The company went IPO on 2017-12-18. The firm offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. The principal activity of the Company is the research, development and manufacture of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. The Company’s services include discovery, engineering and supply. Discovery services includes creation, screening and sequencing of monoclonal antibodies for therapeutic and diagnostic applications. Engineering services includes maximizing the performance of an antibody drug including CDRx humanization, Antibody Developability by Design (ADDTM) and RAMP. Supply services includes the production of material for clinical production or further research, including cGMP ready stable cell line development and transient expression.

FAB Intrinsic Value
5.76 GBX
Overvaluation 6%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-90.3%
=
Net Income
-1.6m
/
Revenue
1.8m
What is the Net Margin of Fusion Antibodies PLC?

Based on Fusion Antibodies PLC's most recent financial statements, the company has Net Margin of -90.3%.

Back to Top